Abstract
127TiP PROPEL: A phase I/II trial of bempegaldesleukin (NKTR-214) in combination with pembrolizumab (pembro) in patients (pts) with advanced solid tumours
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have